Back

Hyperuricemia impaired nitric oxide bioavailablity and deteriorated pulmonary arterial hypertension via a uric acid transporter, URATv1 in xanthine oxidoreductase (XOR)-independent manner

1 September 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Pulmonary Hypertension: Targets for Therapies Hypertension, Pulmonary Hypertension ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Takanori Watanabe

Kyushu University Hospital, Fukuoka (Japan)

6 More presentations in this session

Presentation thumbnail
A novel three-dimensional visualization system revealed an essential adaptive angiogenic response during the early phase of pulmonary hypertension
Doctor T. Fujiwara (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Empagliflozin treatment does not affect the hypertensive response to Ang II administration to rats but decreases oxidative stress in the arterial wall, and endothelial and cardiac dysfunction
Professor V. Schini-Kerth (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Pulmonary hypertension: reduction of vascular and cardiac remodeling by a new inhibitor of p38-alpha MAPK
Miss G. Silva (Rio de Janeiro, BR)
Abstract Slides Video
Presentation thumbnail
Selective inhibition of Histone deacetylases reverses vascular remodelling and improves right ventricle function in pulmonary hypertension
Doctor K. Kurakula (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Beta3-adrenergic stimulation restores endothelial mitochondrial dynamics and prevents pulmonary arterial hypertension
Doctor E. Oliver (Madrid, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary Hypertension: Targets for Therapies

The Event

Event poster

ESC Congress 2020

1 September 2020 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources